Oragenics (OGEN) Interest Expenses (2010 - 2026)
Oragenics' (OGEN) quarterly Interest Expenses came in at $3727.0 in Q1 2026, down 98.13% YoY from $199127.0 in Q1 2025, and down 50.0% on a QoQ basis from $7454.0 in Q4 2025.
Oragenics (OGEN) Interest Expenses (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Interest Expenses data on file, last reported at $3727.0 in Q1 2026.
- Quarterly Interest Expenses fell 98.13% year-over-year to $3727.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $590530.0 (up 166.16% YoY) and the FY2025 annual result came in at $46.3 million, up 1153.6% from the prior year.
- Interest Expenses fell to $3727.0 in Q1 2026, from $7454.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $572310.0 in Q2 2025 to a low of $1803.0 in Q2 2024.
- A 5-year average of $78743.6 and a median of $10969.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 99.32% — and 2025, when it jumped 31642.1%.
- Tracing OGEN's Interest Expenses over 5 years: stood at $5813.0 in 2022, then soared by 368.67% to $27244.0 in 2023, then tumbled by 59.74% to $10969.0 in 2024, then tumbled by 32.04% to $7454.0 in 2025, then slumped by 50.0% to $3727.0 in 2026.
- The last three Interest Expenses figures came in at $3727.0 (Q1 2026), $7454.0 (Q4 2025), and $7039.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 414.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 414.00 |
| Jun 30, 2026 | 414.00 |
| Mar 31, 2026 | 3,727.00 |
| Mar 31, 2026 | 3,727.00 |
| Dec 31, 2025 | 7,454.00 |
| Dec 31, 2025 | 7,454.00 |
| Sep 30, 2025 | 7,039.00 |
| Sep 30, 2025 | 7,039.00 |
| Jun 30, 2025 | 572,310.00 |
| Jun 30, 2025 | 572,310.00 |
| Mar 31, 2025 | 199,127.00 |
| Mar 31, 2025 | 199,127.00 |
| Dec 31, 2024 | 10,969.00 |
| Dec 31, 2024 | 10,969.00 |
| Sep 30, 2024 | 9,971.00 |
| Sep 30, 2024 | 9,971.00 |
| Jun 30, 2024 | 1,803.00 |
| Jun 30, 2024 | 1,803.00 |
| Mar 31, 2024 | 7,085.00 |
| Mar 31, 2024 | 7,085.00 |